Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show, Webcast

Puma Biotechnology to Present at the Barclays Global Healthcare Conference


Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at the Barclays Global Healthcare Conference, which will be held virtually from March 9-11, 2021. Puma's presentation will take place at 1:50 p.m. EST (10:50 a.m. PST) on Thursday, March 11, 2021.

A live webcast of the presentation will be available on the Company's website at www.pumabiotechnology.com. The presentation will be archived on the website and available for 30 days.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.


These press releases may also interest you

at 07:05
BioStable Science & Engineering, Inc. ("BioStable") announced today the company has received CE Mark approval for the HAART 200 Aortic Annuloplasty Device for use during bicuspid aortic valve repair. With CE Mark approval of both the HAART 300 and...

at 07:05
Online tests and assessments dramatically cut down on marking time and can successfully guard against cheating, according to a new study by digital leader Fujitsu and one of the leading universities in Japan. The results demonstrate how learning...

at 07:05
Yelp Inc. , the company that connects people with great local businesses, today released first quarter 2021 data for the Yelp Economic Average (YEA) report, a benchmark of local economic strength in the U.S. The Q1 2021 YEA shows strong signals of...

at 07:05
Nimbus Therapeutics, a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, announced the expansion of its development team with the appointment of accomplished professionals in three key...

at 07:05
RingCentral, Inc. , a leading provider of global enterprise cloud communications, video meetings, collaboration, and contact center solutions, today announced that it was named a Customers' Choice in the April 2021 Gartner Peer Insights ?Voice of the...

at 07:05
Applied DNA Sciences, Inc. ("Applied DNA" or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today provided a preliminary estimated revenue range for the fiscal second quarter ended March 31, 2021 and a business...



News published on 4 march 2021 at 16:20 and distributed by: